StonvexLoading…
StonvexStonvexStonvexCore line items from AKBA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2026 (Est.) Expected 2026-08-05 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $51.96M | $53.54M | $236.20M | $178.57M | $119.81M |
Operating Income | Not available | $-4.70M | $23.50M | $32.05M | $27.60M |
Net Income | Not available | $-9.05M | $-5.34M | $6.90M | $247.00K |
EPS (Diluted) | $-0.04 | $-0.03 | $-0.02 | $0.03 | $0.02 |
Total Assets | Not available | $362.52M | $376.56M | $364.15M | $345.60M |
Total Liabilities | Not available | $335.14M | $343.95M | $322.56M | $316.37M |
Cash & Equivalents | Not available | $162.64M | $184.84M | $166.44M | $137.31M |
Free Cash Flow OCF − CapEx | Not available | $-21.27M | $67.70M | $36.64M | $8.61M |
Shares Outstanding | Not available | 267.90M | 265.42M | 265.23M | 263.04M |